


CLAIM AMENDMENTS

1- 73. (canceled)

74. (new) A compound of the formula (I):



or a salt, solvate or N-oxide thereof, wherein

E is O, S or NH;

G is selected from hydrogen; carbocyclic and heterocyclic groups having from 3 to 12 ring members; and acyclic C₁₋₈ hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the acyclic C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹; provided that E-G is not OH or SH and further provided that E-G does not contain the group O-O;


two adjacent moieties selected from R³, R⁴, R⁵ and R⁶, together with the carbon atoms to which they are attached, form a fused heterocyclic group having from 5 to 7 ring members and 1, 2 or 3 ring heteroatoms selected from N, O and S; and the other two moieties selected from R³, R⁴, R⁵ and R⁶ are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b

wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is hydrogen or C₁₋₄ hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or =NR^c.

75. (new) A compound according to claim 74 having the formula (II):



or a salt, solvate or N-oxide thereof, wherein

A is a group R² or CH₂-R² where R² is a carbocyclic or heterocyclic group having from 3 to 12 ring members;

B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O;

R¹ is hydrogen or a group selected from SO₂R^b, SO₂NR⁷R⁸, CONR⁷R⁸, NR⁷R⁹ and carbocyclic and heterocyclic groups having from 3 to 7 ring members;

R³ and R⁴ together with the carbon atoms to which they are attached form a fused heterocyclic group having from 5 to 7 ring members and 1, 2 or 3 ring heteroatoms selected from N, O and S;

R⁵ and R⁶ are the same or different and are each selected from hydrogen, halogen,

hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c and R^d are the same or different and each is hydrogen or C₁₋₄ hydrocarbyl;

X^1 is O, S or NR^c and X^2 is =O, =S or =NR^c;


R^7 is selected from hydrogen and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^8 is selected from R^7 and carbocyclic and heterocyclic groups having from 3 to 12 ring members;

R^9 is selected from R^8 , COR⁸ and SO₂R⁸;

or NR⁷R⁸ or NR⁷R⁹ may each form a heterocyclic group having from 5 to 12 ring members.

76. (new) A compound according to claim 74 having the formula (III):




or a salt, solvate or N-oxide thereof;

in which J, L and M are each independently selected from =N-, -S-, -O- and =CR¹¹, R¹¹ is hydrogen or a group R¹⁰ wherein R⁵, R⁶, E and G are as defined in claim 1, and R¹⁰ is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹;

R^c is selected from hydrogen and C₁₋₄ hydrocarbyl; and

X¹ is O, S or NR^c and X² is =O, =S or =NR^c.

77. (new) A compound according to claim 76 represented by the formula (IV):



78. (new) A compound according to claim 77 wherein R^5 and R^6 are hydrogen or a substituent selected from halogen, hydroxy, cyano, methyl, ethyl, trifluoromethyl, or amino.
79. (new) A compound according to claim 78 wherein R^5 and R^6 are hydrogen.
80. (new) A compound according to claim 77 wherein E-G is any one of the groups A to AI listed in Table 1 below:



































Table 1		
 A	 B	 C
 D	 E	 F
 G	 H	 I
 J	 K	 L

Table 1		
 <p>M</p>	 <p>N</p>	 <p>O</p>
 <p>P</p>	 <p>Q</p>	 <p>R</p>
 <p>S</p>	 <p>T</p>	 <p>U</p>
 <p>V</p>	 <p>W</p>	 <p>X</p>
 <p>Y</p>	 <p>Z</p>	 <p>AA</p>
 <p>AB</p>	 <p>AC</p>	 <p>AD</p>


<u>Table 1</u>		
		
AE	AF	AG
C(O)NH ₂		
AH	AI	

81. (new) A compound according to claim 77 wherein R¹¹ is selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino, carbocyclic and heterocyclic groups having 5 to 7 ring members; and C₁₋₄ hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, and mono- or di-C₁₋₄ hydrocarbylamino.

82. (new) A compound according to claim 81 wherein R¹¹ is selected from amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino, heterocyclic groups having 5 to 6 ring members and containing up to 2 heteroatoms selected from N, O and S; and C₁₋₄ hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, halogen, amino, and mono- or di-C₁₋₄ hydrocarbylamino.


83. (new) A compound according to claim 82 wherein R¹¹ is selected from amino, methylamino, ethylamino, cyclopropylamino, methyl, ethyl, hydroxyethyl and pyrrolyl.

84. (new) A compound according to claim 75 having the formula (V):




or a salt, solvate or N-oxide thereof.

85. (new) A compound according to claim 74 having the formula (VI):



or a salt, solvate or N-oxide thereof, wherein Het' is a heterocyclic group having from 3 to 7 ring members.

86. (new) A compound according to claim 74 having the formula (V):



or a salt, solvate or N-oxide thereof, wherein R¹² represents hydrogen or one or more substituents selected from halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl and trifluoromethoxy.

87. (new) A pharmaceutical composition comprising a novel compound as defined in claim 74 and a pharmaceutically acceptable carrier.

88. (new) A method for the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase, which method comprises administering to a subject in need thereof a compound as defined in claim 74.